Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
UBS
Express Scripts
Federal Trade Commission
Johnson and Johnson
Chubb
McKesson
McKinsey

Generated: January 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208083

« Back to Dashboard

NDA 208083 describes CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, which is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. It is available from one supplier. Additional details are available on the CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE profile page.

The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
Summary for 208083
Tradename:CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
Applicant:Baxter Hlthcare Corp
Ingredient:clindamycin phosphate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 208083
Suppliers and Packaging for NDA: 208083
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE clindamycin phosphate SOLUTION;INTRAVENOUS 208083 NDA Baxter Healthcare Corporation 0338-9545 0338-9545-24 24 BAG in 1 CARTON (0338-9545-24) > 50 mL in 1 BAG (0338-9545-50)
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE clindamycin phosphate SOLUTION;INTRAVENOUS 208083 NDA Baxter Healthcare Corporation 0338-9549 0338-9549-24 24 BAG in 1 CARTON (0338-9549-24) > 50 mL in 1 BAG (0338-9549-50)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 300MG BASE/50ML (EQ 6MG BASE/ML)
Approval Date:Apr 20, 2017TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 600MG BASE/50ML (EQ 12MG BASE/ML)
Approval Date:Apr 20, 2017TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 900MG BASE/50ML (EQ 18MG BASE/ML)
Approval Date:Apr 20, 2017TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Citi
AstraZeneca
Accenture
US Department of Justice
Medtronic
Julphar
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.